Bi-weekly Subconjunctival Injection of Bevacizumab for Corneal Neovascularization after Burn Injury
Open Access
- 25 December 2021
- journal article
- research article
- Published by The Korean Optometry Society and The Korean Contact Lens Study Society in Annals of Optometry and Contact Lens
- Vol. 20 (4) , 164-168
Abstract
Purpose: We report two cases of corneal neovascularization (NV) after burn injury successfully treated by subconjunctival bevacizumab injections at 2-week intervals.Case summary: Three bi-weekly subconjunctival injections of bevacizumab were administered to two patients with corneal NV after burn injury. In our first patient, corneal NV was markedly reduced by bevacizumab injection. The patient exhibited with a clear cornea and improved visual acuity (20/30) after treatment. Eleven weeks after the last injection, the cornea remained clear, with clinical regression of smaller vessels; the improvement in visual acuity was maintained. In the second case, the diameter of the vessels, hemorrhagic lesions, and corneal edema decreased/regressed, with improvement of the visual acuity to 20/25; these improvements persisted for 12 weeks after the last subconjunctival injection.Conclusions: Our results suggest that bi-weekly subconjunctival injection of bevacizumab is well-tolerated and effective for inhibiting chronic corneal NV after burn injury.Keywords
This publication has 17 references indexed in Scilit:
- Subconjunctival Bevacizumab Injection for Ocular Surface Squamous NeoplasiaCornea, 2013
- Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective studyActa Ophthalmologica, 2012
- Corneal Graft Surgery Combined with Subconjunctival Bevacizumab (Avastin)Cornea, 2010
- Bevacizumab Application Delays Epithelial Healing in Rabbit CorneaInvestigative Ophthalmology & Visual Science, 2009
- Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in RabbitsInvestigative Ophthalmology & Visual Science, 2009
- Effect of Subconjunctival Bevacizumab (Avastin) on Experimental Corneal Neovascularization in Guinea PigsCornea, 2008
- Subconjunctival bevacizumab for vascularized rejected corneal graftsJournal of Cataract & Refractive Surgery, 2007
- Ocular angiogenesis: the role of growth factorsActa Ophthalmologica Scandinavica, 2006
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Corneal neovascularizationCurrent Opinion in Ophthalmology, 2001